MAHOGANY: A PHASE 3 TRIAL OF ZANUBRUTINIB PLUS ANTI‐CD20 VERSUS LENALIDOMIDE PLUS RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR OR MARGINAL ZONE LYMPHOMA.

Zanubrutinib is approved in >15 countries, including the United States and European Union, for pts with relapsed/refractory ( I R i / I R i ) marginal zone lymphoma (MZL) who received >=1 anti-CD20-based regimen, based on the single-arm MAGNOLIA trial (Opat et al. I Clin Cancer Res i 2021). B Introduction: b Inhibition of Bruton tyrosine kinase (BTK) has emerged as a strategy for treatment of patients (pts) with B-cell malignancies including indolent non-Hodgkin lymphomas. MAHOGANY: A PHASE 3 TRIAL OF ZANUBRUTINIB PLUS ANTI-CD20 VERSUS LENALIDOMIDE PLUS RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR OR MARGINAL ZONE LYMPHOMA. [Extracted from the article]